Oral toxicities associated with talquetamab in RRMM: insights from REALiTAL and TALISMAN

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses on-target, off-tumor side effects associated with talquetamab in relapsed/refractory multiple myeloma (RRMM). He shares insights from the REALiTAL (NCT06285318) and TALISMAN (NCT06500884) studies, focusing on oral toxicities. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.